PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 20: Articles 9501-10000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Women must have access to contraceptives.
  2. Women segmentation based on contraceptive use.
  3. Women's attitude toward contraceptive agents. [Kvinnors installning till preventivmedel.]
  4. Women's choices. Family planning.
  5. Women's employment, education, contraception and abortion in Kinshasa.
  6. Women's experiences with family planning.
  7. Women's knowledge of emergency contraception.
  8. Women's participation in welfare organization, primary health care utilization, and contraceptive use in Bangladesh.
  9. Women's reproductive health: the role of family planning programs.
  10. Women's satisfaction with Norplant as compared with oral contraceptives.
  11. Women's socioeconomic position, contraceptive use and fertility preferences in Togo.
  12. Women's status and family planning: results from a focus group survey.
  13. Women, involuntary guinea pigs for new birth control vaccine. India. [Kvinner ufrivillige forsokskaniner for ny prevensjonsvaksine. India.]
  14. Workshop on injectable contraceptives.
  15. The World Bank and family planning.
  16. World contraceptive use 1994. [Wallchart]
  17. An X-ray crystallographic study of the nonsteroidal contraceptive agent centchroman.
  18. Yielding impressive results. The Egyptian experience in family planning communication campaign has been an exemplary model for many developing countries.
  19. You are in bed with the Vatican] On family planning during 20 years of work in developing countries. ["You are in bed with the Vatican]" Om barnbegransning i bistandsarbetet under tjugo ar.]
  20. You win some and you lose some -- contraception and infection.
  21. Young unmarried men and women discuss men's role in contraceptive practice.
  22. Yugoslavia: abortion as a preferred method of birth control.
  23. Zimbabwe family planning project evaluation: male motivation and method expansion.
  24. Zimbabwe takes a lead promoting contraceptives.
  25. A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism.
  26. The relationship between HIV infection and cervical intraepithelial neoplasia among women attending two family planning clinics in Nairobi, Kenya.
  27. Absence of an effect of high vitamin C dosage on the systemic availability of ethinyl estradiol in women using a combination oral contraceptive.
  28. Adolescent males' orientation toward paternity and contraception.
  29. Attitude towards family planning in Dharan, east Nepal, implications for the family planning programme.
  30. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
  31. A comparative study of two low-dose combined oral contraceptives: results from a multicenter trial.
  32. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
  33. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill.
  34. Contraception and dyslipidemia.
  35. Contraception in older woman.
  36. Contraceptive practice and attitudes in former Soviet women.
  37. Contraceptive practices in HIV seropositive females in Ireland.
  38. Contraceptive self-efficacy in college women.
  39. Decreased prevalence of Chlamydia trachomatis infection associated with a selective screening program in family planning clinics in Wisconsin.
  40. Diabetes mellitus and fertility control: contraception management issues.
  41. Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls.
  42. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters.
  43. Effect of four combined oral contraceptives on blood pressure in the pill-free interval.
  44. Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids.
  45. Effect of the intrauterine contraceptive device on protein components of human uterine fluid.
  46. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
  47. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins.
  48. Evaluation of the effect of contraceptive prices on demand in eight Western European countries.
  49. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
  50. Impact of contraception on gynecologic cancers.
  51. The influence of community characteristics on the practice of effective contraception.
  52. Long-interval treatment regimen with a desogestrel-containing oral contraceptive.
  53. Measurement of the quality of family planning services.
  54. Modern contraception use in Ethiopia: does involving husbands make a difference?
  55. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women.
  56. Natural family planning. Couples take chances [letter]
  57. Natural family planning. Effective only if used perfectly [letter]
  58. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant)
  59. One-year experience with subdermal contraceptive implants in the United States.
  60. Oral contraceptive use among young women in southern Sweden.
  61. Oral contraceptive use and breast cancer in Indonesia.
  62. Oral contraceptives and breast cancer in northern Italy. Final report from a case-control study.
  63. Oral contraceptives and reproductive cancers: weighing the risks and benefits.
  64. Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives.
  65. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.
  66. Pregnancy and contraception use among urban Rwandan women after HIV testing and counseling.
  67. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception.
  68. Public funding for contraceptive, sterilization and abortion services, fiscal year 1992.
  69. Pulsatile luteinizing hormone secretion during the first and the fourth cycle on two different oral contraceptives containing gestodene.
  70. Residency training in contraception, sterilization, and abortion.
  71. The safety and efficacy issues of progestin-only oral contraceptives -- an epidemiologic perspective.
  72. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials.
  73. Sex, contraception and childbearing before marriage in Sub-Saharan Africa.
  74. Sexual activity, family life education, and contraceptive practice among young adults in Banjul, The Gambia.
  75. Unwanted pregnancies: understanding contraceptive use and benefits in adolescents and older women.
  76. Validity of contraceptive histories in a rural community in Kenya.
  77. Using a marketing approach to improve the demand and use of family planning services: MEXFAM case study.
  78. Reducing discontinuation in family planning programs. [Réduire la discontinuation dans les programmes de planification familiale; Reducción en el abandono de los métodos anticonceptivos en los programas de planificación familiar.]
  79. Using CQI to strengthen family planning programs. [La utilización del PMC para reforzar la planificación familiar.]
  80. Radiology rounds. Intrauterine contraceptive device.
  81. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
  82. Rapid evaluation method guidelines for maternal and child health, family planning and other health services.
  83. Rational use of oral contraceptives in the perimenopausal woman.
  84. Re: W. Bounds et al., Preliminary Report of Unexpected Local Reactions to a Progestogen-Releasing Contraceptive Vaginal Ring. Eur J Obstet Gynaecol Reprod Biol 1993; 48: 123-125. Comment [letter]
  85. Reaching urban women with family planning services in Ahmedabad, India.
  86. The Reality female condom: efficacy and clinical acceptability of a new barrier contraceptive.
  87. Recasting image of contraceptives.
  88. Recent advances of female contraceptive technology in China.
  89. Recent developments in contraception: 1.
  90. Recent experience with and future directions of contraceptive implants and injectable contraceptives.
  91. Recent trends in contraceptive behavior.
  92. Recent trends in family planning and fertility in Jordan.
  93. Recommendations for oral contraception. 10th Meeting of the "Zurich Discussion Group", April 1993. [Empfehlungen zur oralen Kontrazeption. 10. Arbeitstreffen des "Zurcher Gesprachskreises", April 1993.]
  94. Recommendations of the International Symposium on Contraceptive Research and Development for the Year 2000 and Beyond.
  95. Recommendations of the Pre-Conference Seminar on Planning and Implementation of Effective Family Planning / Family Health and Welfare Programmes: some lessons from the Asian and Pacific region.
  96. Regional report on interaction between clients and grassroots family planning workers: implications for programme performance.
  97. Regional variations in female autonomy and fertility and contraception in India.
  98. The relations between family planning and sterility. [Les relations entre la planification familiale et la sterilite.]
  99. The relationship between family planning and infertility advice.
  100. The relationship between HIV infection and cervical intraepithelial neoplasia among women attending two family planning clinics in Nairobi, Kenya.
  101. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms.
  102. The relationship of child survival intervention programs to the practice of contraception: a case study in Indonesia.
  103. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.
  104. Religion, family planning, and abortion [letter]
  105. Religion, family planning, and abortion [letter]
  106. Religion, family planning, and abortion [letter]
  107. Religion, family planning, and abortion [letter]
  108. Religion, family planning, and sexual behaviour [letter]
  109. Religion, family planning, and sexual behaviour [letter]
  110. Religion, family planning, and sexual behaviour [letter]
  111. Religion, family planning, and sexual behaviour [letter]
  112. Religion, family planning, and sexual behaviour [letter]
  113. 1991 Zaire National Immunization Survey. Further analysis of data: family planning module.
  114. 1992 contraceptive social marketing statistics.
  115. 1994 contraceptive procurement tables (CPTs) guidance.
  116. The 3-keto-desogestrel / ethinylestradiol ring: a new parenteral form of hormonal contraception.
  117. 3-month contraceptive injection approved.
  118. 40th anniversary of the International Planned Parenthood Federation (IPPF) [40 Jahre Internationale Gesellschaft fur geplante Elternschaft (IPPF)]
  119. 7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception.
  120. A.I.D.'s family planning program in Honduras.
  121. Abia mobilises men for family planning.
  122. Abnormal fibrinolytic activity in African women taking oral contraceptives [letter]
  123. Abortion and contraception in russia and the former Soviet Union: past and present. [L'avortement et la contraception en russie et dans l'ex-URSS: histoire et present.]
  124. Abortion and contraception in the USSR.
  125. Abortion is a method of family planning.
  126. Abortion, contraception and ethnic minorities.
  127. ABPF / SEATS project: to increase information on family planning and to satisfy the demand in Cotonou. [Projet ABPF / SEATS: accroitre l'information sur le planning familial et satisfaire la demande a Cotonou.]
  128. Acceptability and cost-effectiveness of postpartum and postabortion family planning in a HMO in Bahia, Brazil.
  129. The acceptability and experience of the female condom, Femidom among family planning clinic attenders.
  130. The acceptability of current contraceptive methods to adolescents. [Priemlemost sovremennykh metodov kontratseptsii u podrostkov.]
  131. Access of rural women to family planning service: a study in Bangladesh.
  132. The access to contraception and sterilization.
  133. Accomplishments of China's family planning program: a statement by a Chinese official.
  134. Achieving public health objectives through family planning services.
  135. Achieving self-sufficiency. The Turkey Contraceptive Social Marketing project sold 2.1 million cycles of low-dose pills in 1992.
  136. Actinomyces species associated with intrauterine contraceptive devices and pelvic inflammatory disease.
  137. Actinomycosis of the minor pelvis associated with prolonged use of intrauterine contraceptive devices (IUDs) [Aktinomikoza male karlice udruzena sa dugotrajnom primenom intrauterinog kontraceptivnog uloska (IUD)]
  138. Addressing sexually transmitted diseases in the family planning setting.
  139. Adherence to oral contraceptive regimens in four countries.
  140. Adolescent contraception. [La contraception des adolescentes.]
  141. Adolescent oral contraceptive users' self-efficacy expectations, sources of efficacy information, and intention to terminate tobacco smoking behaviour.
  142. Adolescent sexuality: Part 2. Contraception.
  143. Adolescents and contraceptive advice.
  144. Adolescents and family planning. The case of Zambia.
  145. Advances in family planning.
  146. Advocacy group cites family planning efforts.
  147. Africa's population and family planning dynamics.
  148. Africa: using radio soap operas to promote family planning.
  149. African-American adolescents' knowledge, health-related attitudes, sexual behavior, and contraceptive decisions: implications for the prevention of adolescent HIV infection.
  150. AID awards Planned Parenthood grant.
  151. AIDS and contraception.
  152. AIDS formative study. Report for the Ghana Family Planning and Health Project / National AIDS Control Programme.
  153. AIDS prevention and family planning programs in Latin America: exploring grounds and possibilities of integration. [Script]
  154. Albania: abortion and contraception now legal.
  155. Alternative distribution systems for contraceptive social marketing projects.
  156. Alternatives for reinforcing rural community-based maternal and child health, and family planning services.
  157. Alternatives to traditional approaches in the formulation and implementation of family planning programmes in African countries.
  158. Analysis of contraceptive use: 1968-1991.
  159. Analysis of the demand for family planning. [Analisis de la demanda de planificacion familiar.]
  160. An analysis of the determinants of family planning volunteer workers' performance in Iloilo City.
  161. And the Nile Flows On: baseline survey results. Final report. Family Planning Knowledge, Attitudes and Practices in Egypt: a National Survey.
  162. Antioxidant erythrocyte enzyme activities during oral contraception.
  163. Applying operations research findings to an ongoing family planning program: Pakistan.
  164. Approaches to community-based family planning service delivery in Africa: two decades of operations research.
  165. Are current sources of contraceptive advice adequate to meet changes in contraceptive practice? A study of patients requesting termination of pregnancy.
  166. Are oral contraceptives a more important risk factor than pregnancy in women with congenital antithrombin III deficiency? [letter]
  167. Are we speaking the same language? Women's health advocates and scientists talk about contraceptive technology.
  168. As postcoital contraceptive, mifepristone has few side effects and high efficacy.
  169. Ask the experts: progestin-only contraceptives.
  170. Assessing contraceptive needs during the menopause.
  171. Assessing the risk of ovulation in interaction studies of drugs and oral contraceptives.
  172. Assessing the stages of change and decision-making for contraceptive use for the prevention of pregnancy, sexually transmitted diseases, and acquired immunodeficiency syndrome.
  173. Assessment of the ICDDR,B-based Maternal and Child Health-Family Planning (MCH-FP) Extension Project: Bangladesh.
  174. Attending to the family planning needs of the neglected population in Latin America: future challenges. [Atención a las necesidades de planificación familiar de la población desatendida en América Latina: los desafíos del futuro.]
  175. Attitude of men toward family planning and possibilities of their increased participation in family planning programs. [Einstellung von Mannern zur Familienplanung und Moglichkeiten ihrer starkeren Einbeziehung in Familienplanungsprogramme.]
  176. Attitudes of Czech and Slovak gynecologists toward family planning.
  177. Attitudes of males on contraception: a KAPE survey.
  178. Attributes assigned to contraception by college students: 1985 and 1990.
  179. The availability of family planning and maternal and child health services.
  180. Availability of family planning services: users and never users perspective.
  181. Background briefing book for Ghana Family Planning and Health Project. Based on a review of secondary research (draft)
  182. Badly resolved triad: sexuality, contraception and pregnancy (editorial) [A triade mal resolvida: sexualidade, anticoncepcao e gravidez. Editorial.]
  183. Bangladesh: the Matlab Maternal and Child Health / Family Planning Project.
  184. Barrier contraception: issues and trends.
  185. Barrier contraceptive use and HIV infection among high-risk women in Cameroon.
  186. Barriers to contraceptive use in two areas of Kenya: rural (Bungoma district) and urban (Baba Dogo, Nairobi)
  187. Benefits and risks of combined oral contraceptives.
  188. Benefits and risks of long-acting injectable contraceptives.
  189. Better contraception.
  190. Birth control and abortion in Europe. [Limitation des naissances et avortement en Europe.]
  191. Birth control and its determinants.
  192. Birth control and the amelioration controversy.
  193. Birth control policy, practice and prohibition in the 1930s: the Maternal Health Association of Cleveland, Ohio.
  194. Birth control teaching taboo.
  195. A birth control vaccine is on the horizon for family planning.
  196. Birth control vaccine research.
  197. Birth control vaccines: principles, procedures, and prospects.
  198. Birth, abortion, family planning and child care in Romania.
  199. Birth-control engineering breeds ethical issues.
  200. Bodies, kin, and flow: family planning in rural Jamaica.
  201. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception.
  202. Bone loss, contraception and lactation.
  203. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use.
  204. Boon or burden? The expanding role of family planning clinics as providers of STD, HIV and primary care services.
  205. Breast feeding as a family planning method.
  206. Breast feeding in family planning: why?
  207. Breast-feeding and natural family planning.
  208. Breastfeeding and contraceptive use: survey results and policy implications.
  209. Breastfeeding and the ovulation method of natural family planning [letter]
  210. Building a woman-centred environment for family planning services.
  211. Burkina Faso: integrating maternal and child health and family planning services.
  212. Can a woman breastfeed while using Depo-Provera as an agent for birth control? [Answer to question]
  213. The case for antiprogestins. A report of the Reproductive Health Technologies Project. RU 486: The first in a new generation of birth control.
  214. A case of cerebral infarction in association with free protein S deficiency and oral contraceptive use.
  215. A case of failed emergency contraception [letter]
  216. A case of permanent endometrial hypotrophy after long-term use of oral contraceptives.
  217. Case-control study of risk factors for cervical squamous cell neoplasia in Denmark. III. Role of oral contraceptive use.
  218. Challenges in safe motherhood: key issues in family planning.
  219. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
  220. Changing high-risk behaviors: what have we learned? Family planning.
  221. The changing structure of American families: the bigger family planning issue.
  222. Characteristics of 2,829 women who obtained an abortion at the family planning clinic of the Centre Hospitalier at Universite Laval. [Caracteristiques de 2,829 femmes ayant obtenu un avortement a la clinique de planification des naissances du Centre Hospitalier de l'Universite Laval.]
  223. Characteristics of successful distributors in community-based distribution (CBD) of contraceptives.
  224. Characterizing users of traditional methods of contraception in relation to modern-method users and never-users: a study in Peru.
  225. Charges and payments associated with provision of family planning services.
  226. Childbearing, oral contraceptive use, and breast cancer [letter]
  227. Childbearing, oral contraceptive use, and breast cancer [letter]
  228. China's family planning policy today.

     

  229. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting.
  230. Chlamydial and other microbial tests in the family planning clinic [editorial]
  231. Choice and use-continuation of methods of contraception: a multicentre study.
  232. Cholestasis in a woman taking oral contraceptives. Occasionally it is necessary to rule out associated extrahepatic biliary pathology (letter) [Colestasis en una mujer que esta tomando contraceptivos orales: en ocasiones es necesario descartar una patologia biliar extrahepatica asociada.]
  233. Choosing a contraceptive.
  234. Choosing and using contraceptives: integrating qualitative and quantitative methods in family planning.
  235. Client and provider perspectives on postpartum contraception.
  236. Clinical evaluation of an oral contraceptive containing ethynil-oestradiol (30 mcg) and gestoden (75 mcg)
  237. Clinical experience with a levonorgestrel-releasing intrauterine contraceptive device (LNG-IUD) as a contraceptive and in the treatment of menorrhagia.
  238. Clinical pre-introduction study of the subdermal contraceptive implant Norplant in Bolivia.
  239. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
  240. Clinical tolerance of a combined monophasic contraceptive agent containing a low-dose of ethinyloestradiol and gestodene in adolescents.
  241. Clinical use of Depo-Provera for contraception.
  242. The clinico-morphological and cytological characteristics of the ecto- and endocervix with the use of the oral contraceptive triregol. [Kliniko-morfologicheskie i tsitologicheskie osobennosti ekto- i endotserviksa pri primenenii oralnogo kontratseptiva triregol.]
  243. Close-out report of Pakistan buy-in to the Operations Research and Technical Assistance Strategies for Improving Family Planning Services in Asia and the Near East Project. USAID Contract Numbers: DPE-3030-C-00-0022-00, DPE-3030-Q-00-0023-00. Period of buy-in: September 1991 - June 1993.
  244. Clotting factors after emergency contraception.
  245. Coached client evaluation of family planning counseling training in Zimbabwe.
  246. Collecting village level data for the analysis of the impact of contraceptive availability and accessibility on reproductive change (1969-1979)
  247. Combined oral contraception with desogestrel / ethinyl estradiol: tolerability profile.
  248. Combined oral contraceptives: acceptability and effective use.
  249. Combined oral contraceptives: risks and benefits.
  250. Combined oral estrogen / progestin contraception: practical attitude. Vascular attacks and contraception. [Contraception oestro-progestative: attitude pratique. Accidents vasculaires et contraceptifs.]
  251. Combining family planning and the Expanded Program of Immunization (EPI)
  252. Combining family planning with the Expanded Program of Immunization (EPI)
  253. The comfort level of pharmacists who counsel contraceptive patients.
  254. Comments by the "Information by Phone" department of the Sex Medical Institute on the telephone calls related to sexuality and contraception.
  255. Communication networks, ideation, and family planning in Trishal, Bangladesh.
  256. Community based distribution of family planning in Africa: lessons from operations research.
  257. Community networks and family planning promotion: impact of the "Jiggasha" approach in Trishal, Bangladesh.
  258. Community participation in family planning programs: Thailand's experience.
  259. Community-based distribution (CBD) of low cost family planning and maternal and child health services in rural Nigeria (expansion)
  260. Community-based distribution of contraceptives and selector health supplies.
  261. Community-based distribution of contraceptives in Zaire.
  262. Community-based family planning demonstration program in San Pablo Autopan.
  263. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
  264. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
  265. Comparative study of the effects of three different kinds of oral contraceptives on lipoprotein and apolipoprotein metabolism.
  266. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
  267. Comparative study on the efficacy, acceptability, and side effects of a contraceptive pill administered by the oral and the vaginal route: an international multicenter clinical trial.
  268. Comparing quality of care with contraceptive access.
  269. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
  270. Comparison between Two Payment Models to Physicians in Two Private Family Planning Agencies in Peru. Final report of an operations research project. Participating agencies: Instituto Andino de Estudios de Poblacion y Desarrollo, Asociacion Pro Desarrollo y Bienestar Familiar, the Population Council / INOPAL II, Asociacion Marcelino - Chiclayo. INANDEP / Peru, Contract No. CI92.45A, July 15, 1992 - October 14, 1993. ["Comparacion entre Dos Modalidades de Pago a Medicos, en Dos Agencias de Planificacion Familiar Privada." Informe final. Instituciones participantes: Instituto Andino de Estudios en Poblacion y Desarrollo, Asociacion Pro-Desarrollo y Bienestar Familiar, the Popublation Council, INOPAL II, Asociacion Marcelino - Chiclayo.]
  271. Comparison of contraceptive implant adopters and pill users in a family planning clinic in Baltimore.
  272. A comparison of levonorgestrel implants with depo-medroxyprogesterone acetate injections for contraception.
  273. Comparison of recalled and validated oral contraceptive histories.
  274. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
  275. Complementing family planning with breastfeeding to improve maternal and child health.
  276. Condom conundrums. Why Catholic morality and birth control are not inconsistent.
  277. Condoms and birth control in school clinics [letter]
  278. Condoms and birth control in school clinics [letter]
  279. Condoms and birth control in school clinics [letter]
  280. Condoms and birth control in school clinics [letter]
  281. Condoms and birth-control in school clinics [letter]
  282. Condoms and contraceptives in junior high and high school clinics. What do you think? [editorial]
  283. Confidentiality, contraception, and young people. Explicit guidance at last.
  284. Congressman Beilenson calls for an increase in funding for international family planning services. [Press release]
  285. Considerations for contraception in women with cardiovascular disorders.
  286. Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighborhood controls.
  287. Constraints on effective family planning in urban Sudan.
  288. Consumer baseline study, Ghana, 1993: a nationwide KAP survey on contraceptives, AIDS, malaria and childhood diarrheal disease.
  289. Consumer views of family planning services in Portsmouth and South East Hampshire.
  290. Contextual effects on current use of modern contraceptive methods: service availability of family planning and contraceptive prevalence in rural Colombia.
  291. Continuation and effectiveness of programme and non-programme methods of family planning in Sri Lanka.
  292. Continuation of contraception. [La continuite de la contraception.]
  293. Contraception [letter]
  294. Contraception and abortion in Romania.
  295. Contraception and abortion in Romania.
  296. Contraception and abortion: the deadly connection.
  297. Contraception and adolescents: highlights from a recent NASPAG conference.
  298. Contraception and condom use among two samples of university students: 1982 and 1992.
  299. Contraception and endometriosis. [Contraception et endometriose.]
  300. Contraception and medications. [Contraception et medicaments.]
  301. Contraception and protection against STDs. CERPOD measures use of the Protector condom in Mali. [Contraception et protection contre les MST. Le CERPOD mesure l'utilisation du condom Protector au Mali.]
  302. Contraception and sexually transmitted diseases: interactions and opportunities.
  303. Contraception and sexually transmitted diseases: what can be done? Experiences and thoughts from the Netherlands.
  304. Contraception and the prevention of sexually transmitted diseases.
  305. Contraception and women's health.
  306. Contraception by intrauterine device (IUD) [La contraception par sterilet.]
  307. Contraception choice and sexually transmitted disease.
  308. Contraception during breastfeeding.
  309. Contraception during lactation.
  310. Contraception for specific sub-groups. [La contraception pour des sous-groupes particuliers.]
  311. Contraception for the year 2020.
  312. Contraception in adolescence. [Anticoncepcion en la adolescencia.]
  313. Contraception in Germany: a review.
  314. Contraception in lactating women.
  315. Contraception in older woman.
  316. Contraception in Russia: attitude, knowledge and practice of doctors.
  317. Contraception in Spain.
  318. Contraception in the adolescent.
  319. Contraception in the diabetic woman.
  320. Contraception in women older than 40 years of age.
  321. The contraception paradox.
  322. Contraception with copper intrauterine device (IUD) [Contraception par sterilet au cuivre.]
  323. Contraception, planning centers, sex information: legislative memorandum. [Contraception, centres de planification, information sexuelle: aide-memoire legislatif.]
  324. Contraception. Low-dose pill launched.
  325. Contraception. Recommendations from a group of experts. [Antikonception. Rekommendationer fran en expertgrupp.]
  326. Contraception. Towards healthier infertility.
  327. Contraception: established and new methods. [Empfangnisverhutung: Bewahrte und neue Methoden.]
  328. Contraception: traditional and religious attitudes.
  329. Contraception: what pharmacists should tell their patients.
  330. Contraceptive and sexual practices among single women with an unplanned pregnancy: partner influences.
  331. Contraceptive behavior in some areas of Braga District. [Comportamento contraceptivo in alguns concelhos do Distrito de Braga.]
  332. Contraceptive behavior of Jerusalem women seeking pregnancy counseling, 1980-1989.
  333. Contraceptive choice for women with "risk factors".
  334. Contraceptive choices for behaviorally disordered women.
  335. Contraceptive choices for perimenopausal women.
  336. Contraceptive choices for women with endocrine complications.
  337. Contraceptive choices for women with medical problems.
  338. Contraceptive choices in women with coagulation disorders.
  339. Contraceptive decision-making: a phenomenological approach.
  340. The contraceptive decision: update on methods / considerations.
  341. Contraceptive delivery in the developing world.
  342. Contraceptive discontinuation among white, black, and Hispanic adolescents.
  343. Contraceptive distribution project.
  344. Contraceptive efficacy of a monophasic oral contraceptive containing desogestrel.
  345. Contraceptive efficacy of the diaphragm, the sponge and the cervical cap.
  346. Contraceptive efficacy of the Reality female condom: comparison with other barrier methods.
  347. Contraceptive health programs for adolescents: a critical review.
  348. Contraceptive knowledge, attitudes, and practice in Russia during the 1980s.
  349. Contraceptive logistics: China's experiences.
  350. Contraceptive methods for women with neurologic disorders.
  351. Contraceptive methods in adolescence. [Metodos contraceptivos en la adolescencia.]
  352. Contraceptive methods. [Les methodes anticonceptionnelles.]
  353. Contraceptive methods. [Les methodes contraceptives.]
  354. Contraceptive methods. [Metodos anticonceptivos.]
  355. The contraceptive pill and women's employment as factors in fertility change in Britain 1963-1980: a challenge to the conventional view.
  356. The contraceptive potential of breastfeeding in Bangladesh.
  357. Contraceptive practice and pregnancy in Mexican adolescent mothers.
  358. Contraceptive practice before female sterilization.
  359. Contraceptive practice in women with systemic lupus erythematosus.
  360. Contraceptive practices in Zimbabwe: the influence of educational attainment and personal relationships.
  361. Contraceptive prevalence is twice as high in Matlab as in surrounding areas.
  362. Contraceptive Prevalence Survey, Jamaica 1993. Preliminary report.
  363. Contraceptive prevalence, reproductive health and our common future. The C. Donald Christian Memorial Lecture.
  364. Contraceptive pricing and prevalence: family planning self-sufficiency in Indonesia.
  365. Contraceptive problems in the developed world.
  366. Contraceptive provision to prostitutes in two Birmingham saunas.
  367. Contraceptive requirements and logistics management needs in India.
  368. Contraceptive requirements and logistics management needs in Nepal.
  369. Contraceptive research and development: the unfinished revolution.
  370. Contraceptive revolution revisited: new arrivals, same old rivals.
  371. Contraceptive risk-taking and contraceptive failure among users of female barrier methods.
  372. Contraceptive risk-taking in a medically underserved, low-income population.
  373. Contraceptive services in school-based clinics: the Baltimore experience.
  374. Contraceptive services target youth. Barking and Havering.
  375. The contraceptive situation in Europe.
  376. Contraceptive social marketing 1993 sales report.
  377. Contraceptive technologies in development: many leads, progress slow.
  378. Contraceptive technology, mix and choice.
  379. Contraceptive use discontinuation in the Philippines: components and covariates.
  380. Contraceptive use during lactational amenorrhea: estimates of double coverage among postpartum women using DHS I data.
  381. Contraceptive use failure and continuation based on two methods of contraceptive data collection in Thailand.
  382. Contraceptive vaccines.
  383. Contraceptives and congenital anomalies. ACOG Committee Opinion: Committee on Gynecologic Practice, Number 124 --July 1993.
  384. Contraceptives and informed consent.
  385. Contraceptives and the selected drugs list [letter]
  386. Contraceptives cause infertility. Determinants of decision-making factors in women with knowledge of contraception who resort to induced abortion.
  387. Contraceptives for teenagers -- an ethical issue.
  388. Contraceptives, counselling, and pregnancy in women with sickle cell disease.
  389. The contribution of contraceptive social marketing programs to the sustainability of family planning services.
  390. COPE: helping to improve the quality of family planning services in Africa.
  391. Cost Analysis of Three Services in Private Family Planning Programs. Interim technical report.
  392. Cost and cost-effectiveness considerations in postpartum family planning programs.
  393. Cost effectiveness analysis of family planning programs.
  394. Cost recovery and the true cost-effectiveness of contraceptive provision.
  395. Cost recovery and user fees in family planning.
  396. Counseling for better contraception.

     

  397. Country case study on cost recovery in family planning. Egypt.
  398. The couple KAP-gap: implications for family planning in developing countries.
  399. Critical analysis of the functioning of family planning services. [Analyse critique du fonctionnement des services de PF.]
  400. A critique of contraceptive prevalence rate (CPR)
  401. Cultural, social and economic determinants of contraceptive method choice in Sri Lanka.
  402. Current controversies and future direction of oral contraception.
  403. Current family planning administrative and program record keeping systems: problems for management and for program evaluation?
  404. Current state of the risk / benefit ratio of oral contraceptives. [Estado actual de la relacion riesgo / beneficio de los anticonceptivos orales.]
  405. The current states of contraception and induced abortion in urban China.
  406. Cycle control with desogestrel-containing oral contraceptives -- comparison of a monophasic and triphasic regimen.
  407. Database of family planning operations research studies.
  408. The defilement narratives of the sexual double standard and adolescent females' sexual attitudes and contraceptive, STD / AIDS behaviours.
  409. Defining the "unmet need" for family planning.
  410. Delivering family planning services in the era of AIDS / STDs.
  411. Demand for postpartum family planning: interviews with women and health providers in Kenya.
  412. Demand, cost and financing of Colombian family planning programs.
  413. Demographic impact of the family planning programme in India: a statistical analysis.
  414. The demographic impact of the Philippine family planning program: a tale of two Metro Manilas.
  415. Deontology and contraception. [Deontologia y contracepcion.]
  416. Depo-Provera contraceptive injection.
  417. Deregulating emergency contraception [letter]
  418. Deregulating emergency contraception. Counselling and education may suffer.
  419. Deregulating emergency contraception. Genitourinary clinics offer out of hours service [letter]
  420. Deregulating emergency contraception. Justified on current information.
  421. Deregulating emergency contraception. Service should reflect greater demand after the weekend [letter]
  422. A descriptive study of the factors affecting postpartum adolescent contraceptive use from a Roy framework.
  423. A design of sample registration system: micro computerized system for monitoring demographic dynamics and health and family planning services in rural Bangladesh.
  424. Design quality to increase coverage: the case for family planning. Draft.
  425. Designing a family planning user fee system: a handbook for program managers. Rev. ed.
  426. Desire for additional children and contraceptive use in Pakistan: what is the influence of husbands?
  427. Desire, attitude and supply: why contraceptive use is so high in three Bangladesh family planning programs.
  428. Determinants of contraceptive method choice after first delivery, before first abortion, and after first abortion in East China.
  429. Determinants of contraceptive use in Belize.
  430. Determinants of fertility and the unmet need for family planning in Indonesia.
  431. Determinants of marital contraceptive use in Kinshasa: an explanatory analysis.
  432. Determinants of successful family planning / welfare programmes in Asia.
  433. Determinants of the choice of source for family planning services in Egypt.
  434. Determining the quality of family planning counseling using an analysis of audio-visual taped provider-client interactions: Ghana and Kenya. Summary of preliminary results.
  435. Developing more effective family planning / family health, and family welfare programmes: opportunities for government-NGO collaboration.
  436. Developing national training strategies in family planning logistics: how hard can it be?
  437. Developing national training strategies in family planning logistics: how hard can it be?
  438. Developing strong family planning programmes for the 1990s and the twenty-first century.
  439. Development of a university-based unit and network for family planning operations research.
  440. Development of contraceptive guidelines for providers.
  441. The development of contraceptive technology. Case studies of incentives and disincentives to innovation.
  442. Development of copper male contraceptive. Contribution of India.
  443. Development of the family by community participation in family planning, the Indonesian revolution in human improvement.
  444. Devolution. How will the family planning program be affected when local governments get greater autonomy?
  445. Diagnostic hysteroscopy and IUD contraception. [Hysteroscopie (HSS) diagnostique et contraception par DIU.]
  446. Diagnostic study of contraceptive acceptors in Yaounde.
  447. A diagnostic study of Department of Health training courses for family planning providers.
  448. A diagnostic study to evaluate the prevalence of clinical and non-clinical delivery of Norplant in the Indonesian family planning program.
  449. Differences between women who use general practice and health authority family planning services.
  450. Differences by residence and education in contraceptive failure rates in developing countries.
  451. Differentials in fertility, mortality and contraceptive prevalence amongst tribals in Western India.
  452. A difficult and delicate task: prescribing contraception for adolescents. [Uma tarefa ardua e delicada: prescrever a contracepcao para adolescentes.]
  453. Dilemmas of public sector contraceptive development.
  454. Disseminating clear and practical information on contraception has never been simple. [Diffuser une information claire et pratique sur la contraception n'a jamais ete simple.]
  455. District Contraceptive Prevalence Differentials Study, Kenya: a case study of six districts.
  456. District team problem solving guidelines for maternal and child health, family planning and other public health services.
  457. Documented effect of the morning-after pill. New elements in contraception counseling. [Dokumenterad effekt av dagen efter-metod. Nya inslag i rad om antikonception.]
  458. Does contraception modify the risk of endometriosis?
  459. Does the Philippines need a new contraceptive pill? A focus group report.
  460. Does women's literacy affect desired fertility and contraceptive use in rural-urban Pakistan?
  461. Dwindling family planning funds challenge Jamaica.
  462. The dynamics of contraceptive use in Peru.
  463. The dynamics of education and fertility: evidence from a family planning experiment. [Draft]
  464. Early childbearing, low contraceptive use maintain high fertility in Cameroon.
  465. Early childbearing. Perspectives of black adolescents on pregnancy, abortion, and contraception.
  466. An economic approach to family planning.
  467. Education, contraception and fertility decline in Brazil: an inter-generational study in Rio de Janeiro.
  468. The effect of a clinic-based intervention on condom use barriers, intentions and behavior in a sample of female Planned Parenthood clients.
  469. The effect of child care and family planning costs in Malaysia.
  470. Effect of contraceptive use and other factors on infant and child survival.
  471. Effect of counselling on use-continuation of contraception. Highlights from an IPPF study.
  472. The effect of elevated ovarian hormones on periodontal health: oral contraceptives and pregnancy.
  473. Effect of health education on knowledge of human sexuality and contraception of teenagers from grades VII and VIII in elementary school. [Wplyw medycznej dzialalnosci edukacyjnej na stan wiedzy o zyciu plciowym czlowieka i antykoncepcji u mlodziezy klas VII i VIII szkol podstawowych.]
  474. Effect of nurse-client transaction on female adolescents' oral contraceptive adherence.
  475. Effect of the different phases of the menstrual cycle and oral contraceptives on athletic performance.
  476. The effect of two contraceptive methods --estrogen-progestagen combination and intrauterine device (IUD) -- on inflammatory lesions and cervical intraepithelial neoplasia. [L'influenza di due metodiche contraccettive (EP versus IUD) nei confronti di alterazioni infiammatorie e CIN.]
  477. Effective family planning programs.
  478. Effectiveness and evolution of family planning programs.
  479. The Effectiveness of contraception: clinical observations and laboratory studies of 688 couples by using the Billings method in Shanghai.
  480. Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism.
  481. The effects of levonorgestrel, desogestrel and gestodene on the pulsatile release of luteinizing hormone in oral contraceptive users.
  482. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism.
  483. The effects of mass media on contraception and fertility in African countries.
  484. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
  485. Effects of rural credit programs and women's empowerment on use of contraception in Bangladesh.
  486. Effects of steroid contraceptive pill on the peripheral lymphocyte micronuclei.
  487. Effects of the prolonged use of intrauterine devices (IUDs) and oral contraceptives on iron nutrition. [Efecto del uso prolongado de dispositivos intrauterinos y anticonceptivos orales, sobre la nutricion del hierro.]
  488. Effects of two low-dose oral contraceptives on erythrocyte superoxide desmutase, catalase and glutathione peroxidase activities.
  489. Effects on blood lipid and androgen levels of two triphasic oral contraceptives.
  490. The effects on hemostasis of oral contraceptives containing desogestrel.
  491. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene / ethinylestradiol and norgestimate / ethinylestradiol.
  492. Efficient implementation of the basic state policy of family planning for the control of population growth.
  493. Emergency contraception [letter]
  494. Emergency contraception [letter]
  495. Emergency contraception.
  496. Emergency contraception: time for de-regulation?
  497. Employment based family planning services.
  498. Endometrial suction in luteal phase as a method of late postcoital contraception.
  499. Epidemiology of endometriosis in women attending family planning clinics.
  500. The estrogenic activity of synthetic progestins used in oral contraceptives.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.